RegeneRx JV Updates RGN-259 Regulatory Progress for Dry Eye Syndrome
- Wednesday, July 14, 2021, 7:15
- PR Newswire
- Add a comment
ROCKVILLE, Md., July 14, 2021 /PRNewswire/ — RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) (“RegeneRx”), a clinical-stage drug development company focused on tissue protection, repair and regeneration has released an update from its U.S. joint venture, ReGenTree LLC, regarding its…
About the Author
admin has written 20958 stories on this site.